APLI:CC News and Press, Appili Therapeutics Inc.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, July 02, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmace...

LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL launched and commercial sales ongoing Funding commitments from U.S. Air Force Academy intended to advance ATI-1701 toward an IND submission to the FDA Engaging regulatory authorities to align on ATI-1801 ...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, April 26, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmac...

Aditxt (NASDAQ: ADTX) , a company dedicated to discovering, developing and deploying promising health innovations, has signed a definitive arrangement agreement to acquire  Appili Therapeutics Inc. (TSX: APLI) (OTCQX: APLIF) . Appili is a biopharmaceutical company focused on drug develo...

A look at the top 10 most actives in Canada Argonaut Gold Inc. (AR) rose 1.3% to $0.39 on volume of 7,782,979 shares Voxtur Analytics Corp. (VXTR) fell 5.3% to $0.09 on volume of 3,222,244 shares Nio Strategic Metals Inc. (NIO) fell 7.7% to $0.06 on volume of 2,740,500 shares Toronto-Do...

Assets include the FDA-approved LIKMEZ™, the ATI-1701 tularemia vaccine defense program that has been awarded a USD $14 million non-dilutive award from the DoD, and the ATI-1801 topical formulation Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX),...

Transaction consideration provides a significant premium to the Appili shareholders Combined enterprise expected to provide enhanced synergies and resources to advance key programs NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED S...

HALIFAX, Nova Scotia, March 12, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced a publicat...

FDA approved LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL Additional USAFA funding commitment from the U.S. Air Force Academy, intended to advance the ATI-1701 program toward an IND submission to the FDA Engaging regulatory authorities to align on ATI-18...

Synex Renewable Energy Corporation (SXI:CA) is expected to report for Q2 2024 Dye & Durham Limited (DND:CA) is expected to report for Q2 2024 Economic Investment Trust Limited (EVT:CA) is expected to report for quarter end 2023-12-31 Western Forest Products Inc. (WEF:CA) is expect...